14th World Advanced Therapies & Regenerative Medicine Congress 2018

Date: 16 May 2018 - 18 May 2018

Business Design Centre Ltd
52 Upper Street
N1 0QH
United Kingdom

Website: https://goo.gl/7yPiac

Email: [email protected]

In May 2018 the World Advanced Therapies & Regenerative Medicine Congress, will bring together 800+ attendees and explore the rapidly developing world of ATMPs (Advanced Therapy Medicinal Products). From clinical translation to commercialisation this congress will bring you the most exciting case studies and new data for stem cells, gene therapy, TCRs and gene editing. Experts in every area will help you tackle the process and regulatory hurdles of developing all new therapeutic formats all the way through manufacture and into the clinic.

The event will take place alongside the co-located World Precision Medicine Congress 2018, hosting 300+ speakers, 10 tracks of content across the 3 days, enabling networking opportunities with 800+ leading industry professionals.

For a 15% discount on your conference ticket, quote code ‘PDKM’ at the online checkout

Confirmed speakers include:

  • Susan Solomon, CEO and Co-Founder, New York Stem Cell Foundation
  • Sven Kili, Vice President & Head, Gene Therapy Development, GSK
  • Eric Soller, Vice President of Corporate Development & Strategy, BlueRock Therapeutics
  • Margo Roberts, CSO, Kite Pharma
  • Sue Hill, Chief Scientific Officer, NHS
  • Brad Perkins, Chief Medical Officer, Human Longevity
  • Julia Wilson, Associate Director, Wellcome Trust Sanger Institute
  • Paul P. Tak, Academic Medical Centre, University of Amsterdam; Senior Vice President of Research & Development Pipeline, Chief Immunology Officer, GSK
  • Elizabeth Shpall, Director, MD Anderson Cancer Center
  • Joanne Kurtzberg, Director, Carolinas Cord Blood Bank, Duke University
  • Todd McAllister, Executive Director, Amnion Foundation
  • Colleen Delaney, Founder and Chief Medical Officer, Nohla Therapeutics
  • Ajan Reginald, Chief Executive Officer, Celixir
  • Alain Vertès, Managing Director, NxR Biotechnologies
  • André Choulika, Chairman & Chief Executive Officer, Cellectis
  • Benjamin Shepherd, Director, Therapeutics, Organovo
  • Eduardo Bravo, Managing Director and CEO, TiGenix
  • Giuseppe Mazza, Chief Executive & Scientific Officer, Engitix
  • James Miskin, Chief Technical Officer, Oxford BioMedica
  • Jane Lebkowski, ‎President of R&D, Asterias Biotherapeutics
  • Jeff Abbey, CEO, Argos Therapeutics
  • John Tchelingerian, CEO, Promethera, Biosciences
  • Katy Spink, Chief Operating Officer, Asterias Biotherapeutics
  • Kristin Comella, Chief Science Officer, US Stem Cell Inc
  • Michael Stein, Chairman & CEO, Oxstem
  • Michael West, CEO, BioTime; CEO, AgeX Therapeutics
  • Nick Crabb, Programme Director – Scientific Affairs, NICE
  • Todd McAllister, Executive Director, Amnion Foundation
  • Yen Choo, CEO, Progenitor Therapeutics
  • Zami Aberman, Chairman & CEO, Pluristem Therapeutics

Key topics include:

  • The next generation of ATMPs
  • Regulation, reimbursement & commercialisation for advanced therapies around the globe
  • CRISPR & gene editing
  • Stem cells as a tool for drug discovery
  • What’s next for cell and gene therapy, new era of regenerative medicine?
  • New paradigms in manufacture: gene therapy & viral vectors
  • Clinical development of immunotherapy & cell therapy
  • New frontiers in repair and replacement of diseased tissues & organs
  • Product, process & manufacturing development of ATMPS

For a 15% discount on your conference ticket, quote code ‘PDKM’ at the online checkout


Loading Map....

Related organisations

Send this to a friend